Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who added mepolizumab to their inhaled triple therapy experienced lower annual systemic corticosteroid exposure than those on placebo.
Data presented at the CHEST annual meeting in Phoenix between October 18 and 21, 2026, revealed that mepolizumab consistently reduced annual systemic corticosteroid exposure in patients with COPD and type 2 inflammation across different blood eosinophil thresholds.
The pooled analysis, which examined 2,089 patients from the METREX, METREO, and MATINEE trials, aimed to address the cumulative toxicity associated with repeated steroid courses in COPD management. While systemic corticosteroids are standard for treating exacerbations, they carry risks of complications including hyperglycemia, fractures, sepsis, and venous thromboembolism, according to Medscape.
| Eosinophil Threshold | Mepolizumab Exposure | Placebo Exposure |
|---|---|---|
| ≥ 150 cells/µL | 434.64 mg | 609.95 mg |
| ≥ 300 cells/µL | 354.28 mg | 551.52 mg |
Researchers found that among the 1,713 participants with a blood eosinophil count of at least 150 cells/μL, 967 individuals—or 56%—required corticosteroids for any reason during the study period.
For this group, mean annual exposure reached approximately 435 mg of prednisolone equivalent with mepolizumab compared with 610 mg in the placebo group, marking a 29% reduction. Among the 1,144 participants with counts of at least 300 cells/μL, 631 patients received corticosteroids, with annual exposure averaging 354 mg for those on the biologic versus 552 mg for those on placebo, representing a 36% decrease.
Participants were randomized to receive either 100 mg of subcutaneous mepolizumab or a placebo every four weeks for up to 104 weeks. While low-dose corticosteroid usage remained similar between study arms, researchers observed notable differences in high-dose therapy, defined as 20 mg or more per day.
At the 150 cells/μL threshold, the placebo group spent 5.9% of their days—totaling 11,850 days—on high-dose steroids, while the mepolizumab group spent 4.5% of their days—8,403 days—on the same high-dose regimen.
The benefits of the treatment were primarily driven by a reduction in high-dose corticosteroid use. Among participants with blood eosinophil counts of at least 150 cells/µL, those in the placebo group spent 5.9% of their days on high-dose therapy, compared with 4.5% for those receiving mepolizumab, Medscape noted. A similar trend appeared in the cohort with counts of at least 300 cells/µL, where high-dose usage was 5.1% for placebo and 3.8% for the treatment group.
Researchers said that mepolizumab targets interleukin-5 and is already approved for patients with an eosinophilic phenotype.
“Mepolizumab as add-on to inhaled triple therapy may help reduce corticosteroid burden in COPD, particularly complications and poor outcomes associated with short-term high-dose courses,” Nicola A. Hanania, director of the Airway Clinical Research Center at Baylor College of Medicine, told Medscape.
While the data suggests a potential for reducing the overall steroid burden, Epocrates said that whether these findings translate into a direct decrease in corticosteroid-related complications remains an open question. “Mepolizumab can serve as an add-on to inhaled triple therapy and may reduce SCS burden in COPD, particularly complications associated with short-term high-dose courses, across a wide spectrum of screening blood eosinophil count levels,” Hanania told Epocrates.